MOREPENLAB · NSE
Morepen Laboratories Limited
₹120.9
+0.28% (+₹0.34)
Prev. close
₹120.56
Volume
1,68,16,327
Delivery %
26.8%
As of
18 Sept 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Recommends buying Morepen Laboratories at ₹95, targeting ₹102, with a stop loss at ₹93.” | Vaishali ParekhPrabhudas Lilladher | Morepen Laboratories | PENDING |
Fundamentals
About Morepen Laboratories Limited
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; and home diagnostic products, such as air purifiers, sphygmomanometers, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides OTC and healthcare products, including fever X for fever; Pain X for pain; Fiber-X for constipation; sat isabgol; Acidity X for acidity; Burnol, a first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers over the counter products under the Dr. Morepen brand name. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Sushil Suri B.Sc., F.C.A.
Headquarters
Gurugram
Employees
1,919
Website
morepen.comExchange
View on NSE ↗Key stats
Market cap
₹6,624.76 Cr
P/E ratio (TTM)
47.2
Dividend yield
0.17%
EPS (TTM)
₹2.56
Beta (1Y · daily vs NIFTY 50)
1.62
Beta (5Y · monthly vs NIFTY 50)
1.54
Shares float
30.89 Cr
EPS · quarter ended Jun 2026
₹1.03
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.3% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,188.06 Cr | ₹1,546.83 Cr | ₹1,417.53 Cr | ₹1,690.43 Cr | ₹1,811.58 Cr | ₹1,805.69 Cr | |
| EBITDA | ₹130.58 Cr | ₹161.71 Cr | ₹85.67 Cr | ₹172.60 Cr | ₹192.43 Cr | ₹172.77 Cr |
| ₹97.00 Cr | ₹102.00 Cr | ₹38.68 Cr | ₹96.16 Cr | ₹118.02 Cr | ₹94.88 Cr | |
| Diluted EPS | ₹2.15 | ₹1.96 | ₹0.77 | ₹1.88 | ₹2.2 | ₹1.73 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹858.00 Cr | ₹1,070.00 Cr | ₹1,110.00 Cr | ₹1,293.00 Cr | ₹1,778.00 Cr | ₹1,936.00 Cr | |
| — | — | ₹25.16 Cr | ₹29.00 Cr | ₹105.10 Cr | ₹207.86 Cr | |
| Stockholders' equity | ₹425.00 Cr | ₹579.00 Cr | ₹753.00 Cr | ₹847.00 Cr | ₹1,157.00 Cr | ₹1,247.00 Cr |
Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹50.92 Cr | ₹-57.76 Cr | ₹-91.17 Cr | ₹73.37 Cr | ₹32.06 Cr | ₹32.64 Cr | |
| Investing cash flow | ₹-70.35 Cr | ₹-31.68 Cr | ₹-46.51 Cr | ₹-83.30 Cr | ₹-321.51 Cr | ₹-123.42 Cr |
| ₹47.17 Cr | ₹63.85 Cr | ₹143.54 Cr | ₹5.20 Cr | ₹299.89 Cr | ₹97.40 Cr | |
| Capital expenditure | ₹-40.40 Cr | ₹-67.37 Cr | ₹-45.97 Cr | ₹-81.34 Cr | ₹-214.24 Cr | ₹-160.54 Cr |
| End cash position | ₹41.39 Cr | ₹15.80 Cr | ₹21.67 Cr | ₹16.95 Cr | ₹27.38 Cr | ₹31.19 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Dec 21(2Q) | Mar 22–Mar 22(2Q) | May 22–Jun 22(2Q) | Sep 22–Jun 24(9Q) | Aug 24–Jun 26(9Q) |
|---|---|---|---|---|---|
| Promoter | 34.54% | 38.38% | 36.74% | 38.22% | 35.65% |
| Public | 65.46% | 61.62% | 63.26% | 61.78% | 64.35% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Morepen Laboratories Limited | ₹6,286.67 Cr | ₹120.56 | 44.8 | 5.04 | 7.6% | 0.17 | -0.1% | +124.3% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 29
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
4 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
We Ran A Stock Scan For Earnings Growth And Morepen Laboratories (NSE:MOREPENLAB) Passed With Ease
simplywall.st · 3 days ago